Skip to content

A Clinical Controlled Trial on the Treatment of Pediatric Bronchitis (Spleen Deficiency and Phlegm-Dampness Syndrome) Using Self-Made Cough and Wheezing Ointment Combined with Acupoint Application

A Clinical Controlled Trial on the Treatment of Pediatric Bronchitis (Spleen Deficiency and Phlegm-Dampness Syndrome) Using Self-Made Cough and Wheezing Ointment Combined with Acupoint Application

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600125097
Enrollment
Unknown
Registered
2026-05-21
Start date
2027-01-01
Completion date
Unknown
Last updated
2026-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchitis

Interventions

Trial group:Basic treatment (nebulization inhalation, expectorant therapy, no antibiotics or traditional Chinese medicine) + self-made cough and asthma ointment oral administration (twice daily, 1 spo
Control group:Only receive the same basic treatment (nebulization inhalation, expectorant therapy, no antibiotics or traditional Chinese medicine)

Sponsors

Huadu District Maternal and Child Health Hospital, Guangzhou
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 6 Years

Inclusion criteria

Inclusion criteria: 1. Age 3 to 6 years old; 2. Meeting the diagnostic criteria for acute bronchitis in Western medicine and the syndrome differentiation criteria for spleen deficiency with phlegm-dampness in Traditional Chinese Medicine; 3. Disease duration = 7 days; 4. Not having received similar treatment in either Western or Traditional Chinese medicine; 5. No congenital heart disease, abnormal liver or kidney function, immune deficiencies, blood disorders, or severe malnutrition; 6. The guardian has signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Presence of severe systemic diseases; 2. Allergy to the components of the study drug; 3. Skin damage or infection at the application site; 4. Use of glucocorticoids or immunosuppressants within 1 week prior to enrollment; 5. Participation in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Change in total TCM syndrome score on day 7 of treatment;

Secondary

MeasureTime frame
Time to resolution of cough, sputum production, and auscultatory findings;Improvement rate of individual symptoms;Overall response rate;

Countries

China

Contacts

Public ContactLin Shaoyun

Huadu District Maternal and Child Health Hospital, Guangzhou (Hu Zhong Hospital)

85446425@qq.com+86 133 8000 5833

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 30, 2026